Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.

Original languageEnglish (US)
Pages (from-to)1169-1173
Number of pages5
JournalJournal of diabetes science and technology
Volume10
Issue number5
DOIs
StatePublished - 2016

Keywords

  • Artificial pancreas
  • Continuous glucose monitoring
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions'. Together they form a unique fingerprint.

  • Cite this